Following this activity, participants should be able to: (1) Describe the place in therapy of the newest chemoimmunotherapy options in advanced non-small cell lung cancer and discuss disease-specific factors to consider such as PD-L1 status and genomic aberrations. (2) Summarize clinical evidence for the approvals of cemiplimab-rwlc in combination with platinum-based chemotherapy, and tremelimumab-actl plus durvalumab and platinum-based chemotherapy in aNSCLC. (3) Discuss key patient counseling points for cemiplimab-rwlc in combination with platinum-based chemotherapy, and tremelimumab-actl plus durvalumab and platinum-based chemotherapy.
- Provider:National Comprehensive Cancer Network
- Activity Link: https://education.nccn.org/node/96063
- Start Date: 2024-11-12 06:00:00
- End Date: 2024-11-12 06:00:00
- Credit Details: AAPA Category 1 Credit™️: 1.0 hours
AMA PRA Category 1 Credit™️: 1.0 hours
Nursing: 1.0 hours
Pharmacy: 1.0 hours - Commercial Support: Source: Exelixis - Amount: 0.0 - Is Kind Support: False Source: GlaxoSmithKline - Amount: 0.0 - Is Kind Support: False Source: Menarini-Stemline - Amount: 0.0 - Is Kind Support: False Source: Merck (Any division) - Amount: 0.0 - Is Kind Support: False Source: Regeneron Pharmaceuticals, Inc. - Amount: 0.0 - Is Kind Support: False
- Activity Type: Enduring Material
- CME Finder Type: Online Learning
- Fee to Participate: No, it's free
- Measured Outcome: Learner Knowledge, Learner/Team Competence, Learner/Team Performance
- Provider Ship: Directly Provided
- Registration: Open to all
Subscribe
Login
0 Comments
Oldest